Zydus's US liver drug gets a faster FDA look. A decision comes Nov 2026.
Priority Review trims the standard clock to 8 months. Saroglitazar now has a concrete US timeline.
— 1 earlier story on Zydus Lifesciences Ltd. →What's new
- FDA granted Priority Review to Zydus's NDA for saroglitazar for primary biliary cholangitis.
- The review clock is 8 months, not the standard 10, with a decision due Nov 27, 2026.
- The drug targets patients who don't respond to, or can't tolerate, the standard therapy.
Why this matters
Priority Review is a formal FDA signal the drug may address an unmet medical need. For Zydus, it sets a hard deadline for its most important US specialty asset and moves the program from planning to a concrete regulatory event.
What we're watching
- Whether the FDA requests an advisory committee meeting before the PDUFA date.
- The data package's strength during the 8-month review window.
- Zydus's US commercial launch plans and potential partner tie-ups.
The full read
The FDA gave Zydus's liver drug saroglitazar a faster review clock. Eight months, not ten. Priority Review means the agency sees enough potential for a more focused, accelerated look. The decision date is November 27, 2026. That's a hard deadline. Saroglitazar targets primary biliary cholangitis in patients who fail or cannot tolerate the standard therapy. A US approval would be Zydus's first commercial foothold there in specialty drugs. The company has spent years talking about launch plans. Now it has a date on the calendar. The task is to hold up to sharper scrutiny in the next eight months.
Questions answered
- What is saroglitazar and what does this NDA cover?
- Saroglitazar is Zydus's candidate for primary biliary cholangitis. The application covers its use with ursodeoxycholic acid in non-responders, or alone for those who can't tolerate the standard drug.
- How much time does Priority Review actually save?
- It cuts the FDA's standard review from 10 months to 8. The agency has set a PDUFA target action date of November 27, 2026.
- Is this a new disclosure?
- Yes. Prior filings discussed US launch costs and plans for saroglitazar but never mentioned this specific regulatory milestone or the new timeline.
- Why is this milestone material for a company Zydus's size?
- Saroglitazar is a key asset in Zydus's pivot to specialty therapeutics. An approval would be its first real US commercial foothold in this drug class.
Story so far
All notes on ZYDUSLIFE →- 27 May 2026 · 5:51 PM IST Zydus's US liver drug gets a faster FDA look. A decision comes Nov 2026.
- 1d ago USFDA flags purified talc at Zydus's Baddi plant in Warning Letter